Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity

• Status: Not yet recruiting
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present study is to evaluate the potential adjuvant therapeutic effect of trimetazidine in treatment of acute AlP poisoning-induced cardiotoxicity.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Trimetazidine

Criteria

Inclusion Criteria:

• Patients included in this study will be diagnosed as acute aluminum phosphide poisoning by history and clinical pictures.

• Age is18 years or older.

Exclusion Criteria:

• Pregnant and lactating women.

• Patients with ingestion or exposure to other substances in addition to aluminum phosphide.

• Patients with other major medical conditions (e.g. cardiovascular disease, diabetes mellitus, renal or hepatic failure).